GenSight Biologics S.A.
GSGTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.08 | 1.04 | 0.27 |
| FCF Yield | -67.46% | -120.10% | -24.95% | -6.41% |
| EV / EBITDA | -3.15 | -2.01 | -5.36 | -8.69 |
| Quality | ||||
| ROIC | -776.29% | -2,282.48% | -202.76% | -70.64% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.92 | 0.94 | 1.22 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.56% | -37.84% | -16.24% | 1,740,777.70% |
| Free Cash Flow Growth | 47.56% | 27.44% | -98.04% | -14.09% |
| Safety | ||||
| Net Debt / EBITDA | -1.46 | -1.02 | -0.27 | 1.17 |
| Interest Coverage | -10.18 | -9.42 | -10.50 | -12.99 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.24 | 0.29 | 493.36 | 52.16 |